Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into a Phase IIb clinical trial. On June 17, 2020, Antisense joined PPMD for a webinar update on Antisense Therapeutics’ clinical program, as well as next steps in the upcoming Phase IIb trial.

If you missed the live event, the recording can be found below.

Watch the Recording